Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 98, Issue 5, Pages 477-479Publisher
WILEY-BLACKWELL
DOI: 10.1002/cpt.140
Keywords
-
Categories
Funding
- Centre for Innovation in Regulatory Science, London, UK
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
Ask authors/readers for more resources
Timely access to safe and effective new medicines of societal value is a goal of medicine developers, regulators, and payers. However, medicine development remains a costly and time-consuming activity, with median development times in 2013 of 9.9 years for new molecular entities.(1)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
